Higher risk of myocardial infarction in the first year following 5-fluorouracil treatment

Back

ESC Premium Access

Higher risk of myocardial infarction in the first year following 5-fluorouracil treatment

Session: New insights for acute coronary syndrome pharmacotherapy

Topic: Pharmacotherapy

Speaker: Doctor J. Shanmuganathan (Aalborg, DK)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Jan Walter Dhillon Shanmuganathan

Aalborg University Hospital, Aalborg (Denmark)

0 follower

8 more presentations in this session

Revacept, an inhibitor of platelet adhesion in symptomatic carotid stenosis: Results from a phase II study

Speaker: Assistant Professor K. Groschel (Mainz, DE)

Access

Abstract

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome and multivessel coronary artery disease: a post-hoc analysis of the TROPICAL-ACS trial

Speaker: Assistant Professor K. Rizas (Munich, DE)

Effects of Interleukin-1 blockade with Anakinra on cardiac function in ST-segment elevation acute myocardial infarction: results from the VCUART3 echocardiography study

Speaker: Doctor A. Abbate (Charlottesville, US)

New possibilities of thrombolytic therapy in patients with STEMI according to a multicenter clinical study FRIDOM1.

Speaker: Doctor E. Gerasimets (Moscow, RU)

Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy

Speaker: Doctor L. Lugo Gavidia (Santiago de Queretaro, MX)

Access the full session

New insights for acute coronary syndrome pharmacotherapy

Speakers: Doctor J. Shanmuganathan, Assistant Professor K. Groschel, Assistant Professor K. Rizas, Doctor A. Abbate, Doctor E. Gerasimets...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources